Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04802876
Title Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)
Acronym ACROPOLI
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.